The Challenge's mission for Lyfebulb and CSL Behring is to find new and meaningful ways to help organ transplant recipients, donors, as well as family members better manage their daily problems and improve their overall quality of life.
FREMONT, CA: Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, have declared the eleven patient entrepreneurs selected as finalists for the 2021 Innovation Challenge: Thriving with Transplantation.
The Challenge's mission for Lyfebulb and CSL Behring is to find new and meaningful ways to help organ transplant recipients, donors, as well as family members better manage their daily problems and improve their overall quality of life. The Challenge's eleven finalists were chosen based on the potential of their creative projects to address these issues, as well as their personal story that inspired them to start their business.
"Improving the transplantation process and empowering patients and their family members to succeed in their complex journeys is our ultimate goal within this initiative and partnership with CSL Behring," stated Karin Hehenberger, MD, PhD, Founder & CEO, Lyfebulb. "We see great potential in the solutions put forth by this diverse set of finalists to make a lasting impact on the transplant community and look forward to accelerating their development through this initiative and beyond."
